WebApr 13, 2024 · この試験では、bi 655130 の用量の安全性と有効性を調査します。 これは、テストされた最高の曝露と同様の曝露を達成するようにモデル化され、健康な被験者を対象とした先行する単回および複数回の用量試験で安全かつ許容可能であることが判明しました。 WebDec 24, 2024 · A 5-year Study to Test BI 655130 in Patients With Generalized Pustular Psoriasis Who Took Part in Previous Studies With BI 655130. Available at …

Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in

WebIntroduction: Palmoplantar pustulosis (PPP) is a chronic, inflammatory skin disease, with high disease burden, that is often refractory to treatment. There is a high unmet clinical … WebAny prior exposure to BI 655130 or another IL36R inhibitor biologic. 5. Increased risk of infectious complications (e.g. recent pyogenic infection, any congenital or acquired immunodeficiency (e.g. HIV), past organ or stem cell transplantation), as assessed by the investigator. 6. Relevant chronic or acute infections including active ... incorporated societies changes

ベーリンガーインゲルハイム 新規抗体が難治性の乾癬の治療を …

Weba human disease with BI 655130, a human monoclonal antibody targeted against the interleukin-36R, 21 assessing the safety and efficacy in patients with a flare of … WebA Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis. The safety and scientific validity of this study is the … WebObjective: To investigate the characteristics and associated factors of invasive fungal disease in patients with systemic lupus erythematosus from Southern China. Methods: A … incorporated societies bill 2021